Green Cross-MSD make explosive growth on ‘Zostavax’
‘Zostavax.’ a MSD’s shingles vaccine co-marketed by Green Cross, has shown an amazing uptrend.
According to the industry concerned, Zostavax has drawn a sharp rising curve with approximately KRW 80 billion sales increased by 25% from the 2015’s KRW 65 billion sales.
Zostavax, the only vaccine w...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
